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Abstract
Background: Venezuelan equine encephalitis virus (VEEV) is responsible for VEE epidemics that occur in South and Central
America and the U.S. The VEEV envelope contains two glycoproteins E1 (mediates cell membrane fusion) and E2 (binds
receptor and elicits virus neutralizing antibodies). Previously we constructed E1 and E2 epitope maps using murine
monoclonal antibodies (mMAbs). Six E2 epitopes (E2
c,d,e,f,g,h) bound VEEV-neutralizing antibody and mapped to amino acids
(aa) 182–207. Nothing is known about the human antibody repertoire to VEEV or epitopes that engage human virus-
neutralizing antibodies. There is no specific treatment for VEE; however virus-neutralizing mMAbs are potent protective and
therapeutic agents for mice challenged with VEEV by either peripheral or aerosol routes. Therefore, fully human MAbs
(hMAbs) with virus-neutralizing activity should be useful for prevention or clinical treatment of human VEE.
Methods: We used phage-display to isolate VEEV-specific hFabs from human bone marrow donors. These hFabs were
characterized by sequencing, specificity testing, VEEV subtype cross-reactivity using indirect ELISA, and in vitro virus
neutralization capacity. One E2-specific neutralizing hFAb, F5n, was converted into IgG, and its binding site was identified
using competitive ELISA with mMAbs and by preparing and sequencing antibody neutralization-escape variants.
Findings: Using 11 VEEV-reactive hFabs we constructed the first human epitope map for the alphaviral surface proteins E1
and E2. We identified an important neutralization-associated epitope unique to the human immune response, E2 aa115–
119. Using a 9 A ˚ resolution cryo-electron microscopy map of the Sindbis virus E2 protein, we showed the probable surface
location of this human VEEV epitope.
Conclusions: The VEEV-neutralizing capacity of the hMAb F5 nIgG is similar to that exhibited by the humanized mMAb Hy4
IgG. The Hy4 IgG has been shown to limit VEEV infection in mice both prophylactically and therapeutically. Administration
of a cocktail of F5n and Hy4 IgGs, which bind to different E2 epitopes, could provide enhanced prophylaxis or
immunotherapy for VEEV, while reducing the possibility of generating possibly harmful virus neutralization-escape variants
in vivo.
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Introduction
Venezuelan equine encephalitis virus (VEEV) is a member of the
Alphavirus genus in the family Togaviridae and is maintained in a
natural enzootic cycle between mosquitoes and rodent hosts,
although equines and humans may also be infected in an epizootic
cycle [1]. While VEEV causes high-titered viremia in equines,
resulting in encephalitis with a mortality rate between 30 to 90%,
disease in humans is usually self-limited and consists of fever, chills,
malaise, and severe headaches, with 1 to 4% progressing to severe
encephalitis [2]. Outbreaks of epizootic VEEV (subtypes 1AB and
1C) occur periodically in South and Central America, even
spreading to south Texas, and therefore it is considered an
emerging pathogen [3]. While the last major transcontinental
outbreak of epizootic VEEV occurred in 1969–1971, smaller South
and Central American outbreaks of VEEV 1C have occurred since,
such as the one in Colombia and Venezuela in 1995–1996 [4,5]. In
the mid to late 1990’s outbreaks caused by the usually enzootic
subtype VEEVs occurred in Peru and Panama (VEEV-1D), and in
the Mexican states of Chiapas and Oaxaca (VEEV-1E) [6–9].
www.plosntds.org 1 July 2010 | Volume 4 | Issue 7 | e739VEEV has potential as a bioweapon, principally because of its
low human infective dose, easy production, and capability for
effective transmission by aerosolization [10,11], and it is listed as a
NIAID Category B priority pathogen. Experimental vaccines (TC-
83, C-84) have been used to protect laboratory personnel and
military troops, but are not licensed for general use [12–14]. A
new, live-attenuated vaccine, V3526, developed from a virulent
VEEV infectious clone by site-directed mutagenesis [15], proved
effective in animal studies [16–18], but was associated with adverse
events in phase 1 clinical trials and subsequently abandoned
[19,20].
Alphaviruses have a positive-sense, single-stranded RNA
genome of approximately 11.45 kb enclosed within an icosahedral
nucleocapsid surrounded by a lipid bilayer derived from the
infected cell’s plasma membrane. Two integral membrane
glycoproteins, E1 and E2, are embedded in the lipid envelope
and are assembled as heterodimers into 80 trimeric spikes on the
virus surface [21–25]. Although the crystal structures of the E1
and capsid proteins of several alphaviruses have been solved, no
well-diffracting crystals of either E2 or virus particles have been
obtained [26–28]. However, cryo-electron microscopy (cryoEM)
reconstructions of several alphaviruses have been reported and
have provided insights into probable E1/E2 structure-function
relationships [25,29–32]. The E1 glycoprotein is responsible for
cell membrane fusion, while E2 is primarily involved in receptor
binding and cell entry as well as eliciting VEEV-specific
neutralizing antibodies.
We have previously analyzed the antigenic structure of both the
VEEV E1 and E2 glycoproteins using murine (m) monoclonal
antibodies (MAbs) and defined six E2 epitopes (E2
c,d,e,f,g,h)
involved in VEEV neutralization [33–35]. These epitopes
clustered in a ‘‘critical VEEV E2 neutralization site,’’ and were
mapped to E2 amino acids (aa) 182–207 by sequencing the RNA
of MAb neutralization-escape VEEV variants [36]. Similar E2
neutralization sites have been identified for both Sindbis virus (SV)
(E2 aa170–220) and Ross River virus (RRV) (E2 aa216–251) using
mMAbs [37–39]. The VEEV epitopes E2
c and E2
h are the most
conserved on the E2 glycoproteins of heterologous VEEVs
[33,40].
Specific treatment for VEEV infections is not available;
however, MAbs reacting with the critical neutralization site
demonstrate potent protective activity in a murine model following
either peripheral or aerosol challenge with virulent VEEV
[12,35,41,42]. Moreover, anti-E2
c mMAb 1A4A-1 and anti-E2
g
mMAb 1A3A-9, as well as the humanized anti-E2
c mMAb Hy4
IgG, have been shown to provide post-exposure protection when
administered within 24 hr after virus inoculation [12,43].
Fully human (h) MAbs would be the best choice for clinical
treatment of human infections; however, little is known about the
immunologic specificities of the human antibody repertoire to
VEEV, and no protective hMAbs have yet been isolated,
characterized, or implemented. In this report we have presented
a map of the human VEEV antibody response and determined the
human immunodominant epitopes on the VEEV E1 and E2
proteins. We used phage-display technology to isolate VEEV-
specific hFabs from bone marrow donors known to have
circulating antibodies for VEEV [44–47]. We have characterized
a panel of 11 hFabs for VEEV surface protein specificity, subtype
cross-reactivity, and in vitro virus-neutralizing capacity. Two anti-
E2 hFabs, H6 and F5, one of which (F5) exhibited potent
neutralizing activity, were converted to fully human IgG1
molecules. Two F5 hMAb neutralization-escape VEEV variants
were isolated. Sequencing of the E1 and E2 protein genes of these
variant viruses identified a unique human VEEV neutralization
domain as the likely binding site of the F5 hMAb. Alphavirus
cryoEM maps, with associated markers, support proposing a
probable surface-accessible location on VEEV E2 for the F5 native
(n) IgG binding site.
Methods
Viruses and murine MAbs
The VEE complex viruses used in this study were Trinidad
donkey (TrD, subtype 1, variety AB), vaccine strain TC-83 (1-AB),
P676 (1-C), 3880 (1-D), Mena II (1-E), Everglades (EVE)(2),
Mucambo (MUC) (3-A), Pixuna (PIX) (4), Cabassou (CAB) (5),
and AG80-663 (Rio Negro) (6), which were obtained from the
Division of Vector-Borne Infectious Diseases (DVBID), Centers
for Disease Control (CDC), Fort Collins, CO. Viruses grown in
Vero cells were purified by equilibrium density-gradient centrifu-
gation [48]. Purified VEEV TC-83 used for panning phage display
libraries was inactivated with 0.05% or 0.3% b-propiolactone
(BPL) in 0.1M Tris base, pH 9, for 48 h at 4uC. Virus inactivation
was verified by inoculation of Vero cells, which were monitored
for cytopathic effects (CPE). Inactivated virus was evaluated by
ELISA for preservation of important epitopes reactive with
neutralizing mMAbs [33]. Anti-VEEV neutralizing mMAbs
(3B4C-4, 1A4D-1, 1A3A-9, 1A3B-7, and 3B2A-9) and their
respective neutralization-escape variant viruses used in the
characterization of hMAb F5 nIgG have been well-documented
[33,34,36].
Phage library creation, Fab selection and production of
human anti-VEEV Fabs and MAbs
Total RNA was obtained from bone marrow and blood samples
supplied by two military donors (951, 1037) using Tri-reagent BD
(Molecular Research Center, Inc., Cincinnati, OH) according to
the manufacturer’s instructions. Blood utilized in this project was
obtained under protocol 01-124 approved by Scripps Clinic,
IRB#00001283, Assurance Number FWA00000467. Bone mar-
row samples were obtained from a commercial source. Donor sera
ELISA titers to VEEV TC-83 were 1:500–3000.
Messenger RNA was isolated using Oligotex spin columns
(Qiagen, Valencia, CA) following the manufacturer’s protocol. To
amplify mRNA, first strand cDNA was synthesized using
SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA)
Author Summary
Although the murine immune response to Venezuelan
equine encephalitis virus (VEEV) is well-characterized, little
is known about the human antibody response to VEEV. In
this study we used phage display technology to isolate a
panel of 11 VEEV-specfic Fabs from two human donors.
Seven E2-specific and four E1-specific Fabs were identified
and mapped to five E2 epitopes and three E1 epitopes.
Two neutralizing Fabs were isolated, E2-specific F5 and E1-
specific L1A7, although the neutralizing capacity of L1A7
was 300-fold lower than F5. F5 Fab was expressed as a
complete IgG1 molecule, F5 native (n) IgG. Neutralization-
escape VEEV variants for F5 nIgG were isolated and their
structural genes were sequenced to determine the
theoretical binding site of F5. Based on this sequence
analysis as well as the ability of F5 to neutralize four
neutralization-escape variants of anti-VEEV murine mono-
clonal antibodies (mapped to E2 amino acids 182–207), a
unique neutralization domain on E2 was identified and
mapped to E2 amino acids 115–119.
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was synthesized according to the method fully described in the
patent WO2005/060641A2 [49]. The cDNA was purified with a
PCR purification kit (Qiagen) and single primer amplification was
performed according to the method fully described in the patent.
The amplified products were digested with Xba I/Sac I for the
kappa light chains (LCs), Xba I/Kas I for the lambda LCs, and
Xho I/Age I (Pin AI) for the heavy chains (HCs), and cloned into
Fab expression phagemid vectors PAX243hGK and
PAX243hGL. Two Fab libraries were generated for each donor,
one expressing kappa LCs and one, lambda LCs, and both
utilizing gamma HCs.
Fab-bearing phage from all libraries were panned through one
to four rounds of enrichment against inactivated VEEV TC-83
coated in 96-well plates overnight at 4uC. Wells were washed with
water and blocked 1 h at 37uC with 3% bovine serum albumin
(BSA) in phosphate-buffered saline (PBS). The phage library was
added to the wells and incubated at 37uC for 2 h. Wells were
washed 10 times with PBS containing 0.05% Tween-20 (PBS-T).
The bound Fab-phage were eluted with 2M glycine, pH 2.2,
neutralized with 2M Tris base, used to infect log phase E. coli cells,
strain ER 2738, and amplified by adding helper phage, strain
VCSM13, to the infected bacteria for each round of panning.
Individual colonies were produced by plating infected bacteria.
Screening by ELISA on inactivated VEEV TC-83 virus was
performed in high throughput mode using a Tecan robot (Tecan
Systems Inc., San Jose, CA) for large numbers of colonies (.1000)
picked using a Q-pix instrument (Genetix Inc., Boston, MA).
Individual colonies were grown overnight in deep-well microtiter
dishes in a Hi-Gro high-speed incubator-shaker (GeneMachines,
San Carlos, CA). Aliquots were removed and stored as stocks
containing 15% glycerol or 10% DMSO. After centrifugation of
the deep-well dishes, Fab-containing supernatants were collected
for ELISA screening. Alkaline phosphatase (AP)-labeled goat anti-
human Fab (Pierce Protein-Thermo Fisher Scientific, Rockford,
IL) was used to detect expressed Fab bound to antigen. Miniprep
DNA (Qiagen) from positive colonies was sequenced across the
light and heavy chains using standard primers for the phagemid
expression vectors. Sequences were analyzed using DNAstar
software (DNAstar Inc., Madison, WI) to identify and classify
unique candidates. For soluble Fab expression and purification,
the gene III fusion region of the phagemid was removed from
positive, unique candidates by subcloning. At this stage it was
possible to insert an oligonucleotide that encoded a combination
epitope tag consisting of an influenza virus hemagglutinin (HA tag)
and 6 histidine residues (His tag) for detection and purification
with anti-HA and/or Ni-NTA [50].
Panning and screening of additional libraries were done on
inactivated VEEV TC-83, either with or without epitope masking
by non-neutralizing hMAbs F2 engineered (e) IgG and H6 eIgG to
increase the chances of isolating Fabs with neutralizing capability.
For panning with epitope masking, wells coated with VEEV TC-
83 were incubated with F2 eIgG (50 mg/ml) and H6 eIgG (10 mg/
ml) in 1% BSA-PBS at 37uC for 30 min followed by addition of
library phage and incubation at 37uC for 1.5 h.
Fab/MAb expression and purification
Fabs selected for characterization were cloned into a Fab
expression vector, PAEV1, using Eco RI/Spe I restriction sites
available in the vector (Figure S1A). Two Fabs, K1B11 and
K1H3, which had Eco RI sites in their LCs were cloned into a
PAEV1 vector containing Fab L1A7 LCs and HCs by using the
Xba I/Age I sites (Figure S1B). The selected Fabs were produced
in BL21 E. coli cells with induction by isopropyl-b-D-thiogalacto-
pyranoside and purified on a goat anti-human IgG F(ab9)2 affinity
column. Purified F5 Fab for use as a positive control in ELISA was
prepared from F5 eIgG by papain digestion using an ImmunoPure
Fab Preparation Kit (Pierce) according to the manufacturer’s
instructions.
Four hFabs (F2, F5, G1 and H6) were converted to full-length
IgG1s in a two-step cloning process (Figure S2). The region
between LC and HC (Not I to Xho sites) was replaced with
mammalian control elements, including a poly A signal for the end
of the LC, a human cytomegalovirus promoter to direct expression
of the HC, and an HC mammalian leader sequence. This
intermediate was inserted via restriction sites Sfi I and Age I into a
mammalian expression vector containing additional control
elements and IgG1 HC constant domains. The resulting
‘‘engineered’’ IgG1 differed from the n sequence due to the few
non-n aa codons at three restriction sites (Xba I, Sac I, and Xho I)
present at the N-terminus of both LC and HC. F5 eIgG was then
converted to IgG containing n sequences in three steps using site-
specific mutation and overlap PCR (Figure S3). The sequences of
all constructs were verified.
HMAbs were produced by transfecting 120 ml of 293-EBNA
cells (3.75610
5 cells/ml) with 64 mg of MAb expression vector
DNA using Effectene (Qiagen) according to the manufacturer’s
protocol. The culture supernatant was harvested 5–7 days after
transfection and each MAb was purified on a protein A column
using FPLC. Stable cell lines producing F5 nIgG were established
by selecting transfected 293-EBNA cells with puromycin (10mg/
ml). The transfected cells were initially grown in 24-well plates and
medium was screened by ELISA using a goat anti-human IgG
F(ab9)2 antibody-AP conjugate (Jackson ImmunoResearch, West
Grove, PA) for detection. The 2 wells with the highest antibody
expression were chosen for single cell selection in four 96-well
plates. Wells containing single-cell colonies were tested by ELISA
and the best producers were chosen for expansion. One of these
clones, IE9, was grown in 1.5 L and 6 L cultures that produced
25 mg and 50 mg MAb, respectively, after protein A column
purification. The purified antibody showed specific binding to
inactivated VEEV TC-83 that was comparable to that of F5 nIgG
prepared from transient transfection of 293-EBNA cells.
The GenBank accession numbers for the F5 nIgG light and
heavy chain variable region sequences are HM047070 and
HM047071, respectively.
Serological tests for Fabs and MAbs
Indirect ELISAs were used to verify VEEV binding by purified
hFabs and to determine the cross-reactivity of selected hFabs and
hMAbs to six VEEV subtypes and four varieties of subtype 1.
ELISAs were performed essentially as previously described
[43,51]. Fab or MAb binding to purified virus was detected by
goat anti-human IgG F(ab9)2- or Fc-specific-AP conjugates
(Jackson ImmunoResearch). An absorbance ratio (A405 test
sample/A405 negative control) .2 was considered to be positive.
Competitive binding assays (CBAs) were used to determine the
ability of F5 nIgG to block the binding of anti-VEEV neutralizing
mMAb-horseradish peroxidase (HRP) conjugates, and, conversely,
the ability of purified mMAbs or hFabs to block the binding of F5
nIgG-HRP to virus. A dilution of each unconjugated mMAb,
hMAb, or hFab that resulted in approximately 70% binding to
VEEV TC-83 was determined by titration in an indirect ELISA,
using either AP-conjugated goat anti-mouse IgG (Fc-specific) or
goat anti-human IgG [F(ab9)2-specific] as a detector and Sigma
104 phosphatase substrate. Reactions were read at 405 nm.
Dilutions of MAb conjugates that resulted in an A405 of
approximately 1.0 were also determined for use in CBAs. For
VEEV Human Epitope Map
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1 mg VEEV TC-83 overnight and then blocked with 3% goat
serum in PBS for 1 h at 37uC. MAb or Fab competitors were
added at predetermined dilutions, serially diluted 1:2 in PBS-T,
and incubated at room temperature for 30 min. A previously
determined constant dilution of MAb-HRP in blocking buffer was
added to each serially-diluted competitor and incubated for 1 h at
37uC. One hundred ml premixed tetramethyl benzidine substrate
(Neogen Corp., Lexington, KY) was added to each well, the
reaction was stopped in 15–30 min with 50 ml1 NH 2SO4, and
plates were read at 450 nm.
Viral protein specificity of each antibody was determined by
immunoblot using precast 8% Tris-glycine gels (Invitrogen) for
fractionation of purified VEEV TC-83, 1 or 2 mg per lane, under
both reducing and non-reducing conditions for 110 min at 125
volts. Electroblotting onto 0.2 mm nitrocellulose membranes using
a Novex XCell blotting apparatus (Invitrogen) was done according
to the manufacturer’s protocol. Membranes were blocked with
StartingBlock buffer (Pierce) at 4uC to prevent nonspecific binding.
Membrane strips were incubated with the purified hMAbs and
hFabs as well as protein E1- and E2-specific mMAbs for 2 h at
room temperature, followed by incubation with either AP-
conjugated goat anti-human IgG F(ab9)2 or goat anti-mouse IgG
(Jackson ImmunoResearch) for 1 h, and then visualized with 5-
bromo-4-chloro-3-indolyl-phosphate/nitroblue tetrazolium phos-
phatase substrate (Kirkegaard and Perry Laboratories, Gaithers-
burg, MD). The PRNT for IgG or Fab antibody fragments was
performed essentially as previously described [43].
Selection and genome sequencing of F5 nIgG
neutralization-escape variants of VEEV TC-83
Neutralization-escape variant viruses were selected with F5
nIgG using an infectious clone of VEEV TC-83, pVE/IC-92, in a
manner similar to that used previously to select escape variant
viruses for neutralizing mMAbs [36,52]. In this case, different
amounts of purified MAb F5 nIgG (6 replicates each of 50 mg,
5 mg, and 0.5 mg) were incubated with approximately 100 pfu of
virus for 1 h at 37uC and then plated on Vero cell monolayers in
6-well plates. Well-isolated plaques were cored, eluted overnight at
4uC, and 0.5 ml of the eluted virus from each sample was
incubated with 25 mg (5 ml) of F5 nIgG for 1 h at 37uC. Each
sample was then adsorbed to Vero cells containing 50 mg MAb/ml
in the culture medium and monitored for CPE. Supernatant was
collected from this second selection cycle from wells showing CPE
and the virus seed was passed once in Vero cells without addition
of F5 nIgG.
Two variant viruses were isolated and RNA was extracted from
140-ml aliquots of seed virus from the variant and parent viruses
using the QIAamp viral RNA Kit (Qiagen) following the
manufacturer’s instructions. RNA was eluted in 30–40 mlo f
nuclease-free water and stored at 280uC. Amplimers for
sequencing the glycoprotein-coding region of pVE/IC-92 and
the two variant viruses were generated by standard RT-PCR
performed with either 5 or 10 ml of template RNA and 20 pmol of
each primer (Table S1) in a 50 ml-reaction using the Titan RT-
PCR Kit (Roche Molecular Biochemicals, Indianapolis, IN),
following the manufacturer’s protocol. Initial RT was performed
at 50uC for 30 min, followed by denaturation at 96uC for 2 min.
PCR included 10 cycles of 96uC for 20 sec, 52uC for 30 sec, 68uC
for 2.5 min; 25 cycles of 96uC for 20 sec, 52uC for 30 sec, 68uC
for 2.5–6.7min; and a final extension at 68uC for 7 min in a DNA
Engine Thermocycler (BioRad, Hercules, CA). The resulting
amplimers were gel purified using a QIAquick Gel Extraction Kit
(Qiagen), essentially following the manufacturer’s protocol.
Approximately 20–30 ng of each amplimer was used for direct
sequencing using a 9800 Fast Thermocycler, a Big Dye automated
DNA sequencing kit, and a 31306l Genetic Analyzer (Applied
Biosystems, Foster City, CA).
Results
Generation of human MAbs and Fabs for VEEV
Bone marrow specimens with matched sera donated by VEEV
seropositive, active service military personnel were provided to
Alexion Antibody Technologies (AAT), San Diego, CA, from a
commercial source. The human donor sera were tested against
inactivated VEEV TC-83 using an indirect ELISA. Only
inactivated VEEV was used at AAT; both native and inactivated
VEEV were used at DVBID, CDC, and Colorado State
University, Fort Collins, CO. Two donor bone marrows, 951
and 1037, were selected for use in constructing phage display
libraries. Large libraries, 2.6–5.7610
9 phage particles per ml, were
obtained and panned through four rounds on inactivated VEEV
TC-83. A panel of hFab clones from panning rounds three and
four for each of four libraries (951k, 951l, 1037k, and 1037l) was
screened on VEEV TC-83 as well as 1% BSA (negative control).
Three hFab clones with the highest ELISA signals from each of
the four libraries were selected for sequence analysis. The
sequencing results (not shown) showed that all three 951k clones
were identical. Ten of the 12 clones had the same variable HC
region, but the majority of those Fabs had different LC sequences.
In all, there were 10 unique clones in three separate HC
groupings. Four hFab clones, P3F2, P3F5, P3H6, and P3G1,
were expressed as soluble molecules and purified by Ni-NTA
column chromatography for use in serological assays. These four
clones were also converted to full-length IgG1 molecules (Figure
S2). Because the P3F5 clone had significant VEEV-neutralizing
ability, a stable cell line expressing F5 nIgG was generated in 293-
EBNA cells.
An attempt was made to identify additional anti-VEEV hFabs
using libraries from donors 951 and 1037. In this case the VEEV
TC-83 used for panning and screening was inactivated with 0.05%
BPL; previously the virus used for these procedures was
inactivated with 0.3% BPL, a concentration subsequently shown
to reduce the binding of F5 eIgG and F5 nIgG (Table S2). Panning
was done with and without epitope masking with non-neutralizing
hMAbs F2 eIgG and H6 eIgG in order to increase the probability
of isolating Fabs with neutralizing ability. Nine new hFabs were
isolated, four using the epitope masking protocol (K1B11, K1H3,
L1A7, and K2E2) and five without masking (LR3H11, KR2A3,
KR2B12, KR2C2, and 951-D3).
Antibody binding characteristics and sequence analysis
of heavy and light chain complementary determining
region 3
HMAbs were titrated on VEEV TC-83 by ELISA (Figure S4).
The three hMAbs and mMAb 3B4C-4 had similar binding
affinities for TC-83, with titers of approximately 3 ng/ml. All the
hFabs had endpoint titers of 5–20 ng/ml with the exception of
L1A7 which had a titer of approximately 0.5 mg/ml (Fig. S5).
The viral protein specificities of the hMAbs and hFabs were
determined by immunoblot using purified VEEV TC-83 separat-
ed by PAGE under both reducing and non-reducing conditions.
Seven of 11 antibodies were specific for the E2 glycoprotein and
four for E1. All the E2-specific antibodies recognized both reduced
and non-reduced protein, whereas the E1-specific antibodies lost
reactivity after proteins were subjected to reducing conditions
(exposure to 2-mercaptoethanol) (Table 1).
VEEV Human Epitope Map
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cross-reactivity with nine VEEVs, representing four subtype 1
varieties as well as subtypes 2–6 (Table 1). HMAb epitope
designations were based on the number and specificity of the
VEEV subtypes and varieties recognized by each antibody in
ELISA and the sequence data for MAb and Fab HC and LC
complementary determining region 3 (HCDR3, LCDR3)
(Tables 1,2). The cross-reactivity analysis is also presented in
graphical form since antibodies with similar cross-reactivities had
unique titration curves when antibody concentration was plotted
versus absorbance at 405 nm (Figures 1, 2). Sufficient amounts of
MAbs F2 eIgG and G1 eIgG were not available to determine
ELISA cross-reactivity but each was shown to be specific for E2 by
immunoblot and to have PRNT endpoints of $10mg/ml (data not
shown).
H6 eIgG, assigned to epitope hE2
a1, was the most cross-reactive
of the anti-E2 MAbs characterized, reacting with all the VEEV
subtypes and varieties tested except subtype 4 (Table 1, Figure 1).
MAbs F2, G1, and H6 had the same HCDR3 aa sequence, but
different LCDR3 sequences, which might indicate that these
Table 1. Characterization of human MAbs and Fabs for Venezuelan equine encephalitis virus (VEEV).
Epitope mg MAb MAb
A 1AB
B 1C 1D 1E 2 3 4 5 6 PRNT
C Immunoblot
D
hE2
a1 1 H6 eIgG ++ ++ ++ ++ ++ ++ 2 ++ ++ .10 +/not tested
hE2
a2 1 LR3H11 ++ ++ ++ ++ ++ + 2 ++.100 +/+
hE2
b 1 KR2A3 ++ ++ ++ + ++ + 2 ++.100 +/+
hE2
b 1 KR2B12 ++ ++ ++ + ++ + 2 ++.100 +/+
hE2
b 1 KR2C2 ++ ++ ++ ++ ++ + 2 ++.100 +/+
hE2
c 1 F5 nIgG ++ ++ ++ ++ ++ ++ 22++ 0.01 +/+
hE2
d 10 951 D3 + + +++ + 22222. 100 +/+
mE2
c 100 Hy4 IgG ++ ++ + 2 ++ 2222, .004 +/+
hE1
a 1K 1 B 1 1
E ++ ++ ++ ++ ++ ++ + ++ ++ .100 +/2
hE1
a 1 K1H3
E ++ ++ ++ ++ ++ ++ + ++ ++ .100 +/2
hE1
b 10 L1A7
E ++ ++ ++ 2 ++ + 2 + 2 2–3.1 +/2
hE1
c 1 K2E2
E ++ ++ ++ 2 ++ ++ ++ ++ ++ .100 +/2
AMAb tested as full antibody (H6, F5, and Hy4) or Fab. Hy4 IgG is a humanized mouse (m) MAb; all other antibodies are human (h).
BCross-reactivity reported as percent of each MAb’s reactivity with subtype 1AB (VEEV TC-83); ++ (.50%), + (25–50%) and 2 (,25%). Viruses used for each subtype: 1C
(P676), 1D (3880), 1E (Mena II), 2 (Everglades), 3 (Mucambo), 4 (Pixuna), 5 (Cabassou), and 6 (AG80-663).
CAntibody endpoint concentration (mg/ml) in a 70% plaque-reduction neutralization test (PRNT) with VEEV TC-83.
DAntibody reactivity by immunoblot on nonreduced/reduced VEEV TC-83 antigens.
EFabs isolated using epitope masking with anti-E2 hMAbs F2 eIgG and H6 eIgG during the panning process.
doi:10.1371/journal.pntd.0000739.t001
Table 2. Amino acid sequences of both heavy and light chain complementary determining region 3 of human MAbs and Fabs for
Venezuelan equine encephalitis virus.
Epitope Type
A Antibody HCDR3
B LCDR3
C
ND
D eIgG F2 QLWFGELFGHDVFDI QQYHNWPPLT
ND eIgG G1 QLWFGELFGHDVFDI AAWDDSLNGPV
hE2
a1 eIgG H6 QLWFGELFGHDVFDI QVWDSSSDHVV
hE2
a2 Fab LR3H11 DTDPFAVLVLAATPADY CSYAQRFTWV
hE2
b Fab KR2A3 DTDPFAVLVLAATPADY QQFNDYPAT
hE2
b Fab KR2B12 DTDPFAVLVLAATPADY QQFNDYPAT
hE2
b Fab KR2C2 DTDPFAVLVLAATPADY QQANSFPLS
hE2
c eIgG, nIgG F5 DGAYYYDYSGYPYDYNGIDV AAWDDSLNGWV
hE2
d Fab 951 D3 DGGLSEYNYYYYYMDV QQYYHSPPT
hE1
a Fab K1H3
E VKCSSTSCYPWDYYGMDV QQYNNYPVT
hE1
a Fab K1B11
E VKCSSTSCYPWDYYGMDV QQYNTYPWT
hE1
b Fab K2E2
E EENSGYDY QQSYTTPQYT
hE1
c Fab L1A7
E DGAYYYDDSGYPYSYSGIDV AAWDDSLNGWV
AAntibody used in the form of engineered (e) human IgG, native (n) human IgG or Fab.
BHCDR3, heavy chain complementary determining region 3; amino acid sequence.
CLCDR3, light chain complementary determining region 3; amino acid sequence.
DND, not done.
EFabs isolated using epitope masking with anti-E2 MAbs F2 eIgG and H6 eIgG during the panning process.
doi:10.1371/journal.pntd.0000739.t002
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LR3H11 was assigned to epitope hE2
a2 based on the similarities of
its ELISA titration curve to that for the anti-hE2
a1 MAb (Figure 1)
and its cross-reactivity (Table 1), and on differences in HCDR3
and LCDR3 sequences (Table 2). LR3H11 had a generally lower
level of reactivity to all the VEEV subtypes (especially subtypes 3,
5, and 6), compared to H6 eIgG. The higher reactivity level of H6
eIgG compared to Fab LR3H11 could be due to the fact that H6
is a complete IgG molecule. Although the HCDR3 sequence is the
same for LR3H11 and the anti-hE2
b Fabs, the LCDR3 sequences
are completely different (Table 2). The three anti-hE2
b Fabs,
KR2A3, KR2B12, and KR2C2, have identical HCDR3 sequenc-
es and the LCDR3 sequences are 44 to 100% similar (Table 2).
Fabs KR2A3 and KR2B12 have the same sequence throughout
except for one aa change in framework region 2 (Lys to Arg). In
addition, this group of Fabs had a distinct reactivity profile
consisting of three reactivity groups (curves) which included the
following subtypes and varieties: (1) 1AB, 1C, 1D, 2; (2) 1E, 3, 5, 6;
and (3) 4 (Figure 1). MAb F5 nIgG had a unique cross-reactivity
pattern and unique HCDR3/LCDR3 sequences as well as potent
viral neutralizing activity, and was assigned to epitope hE2
c
(Tables 1, 2; Figure 1). Fab 951 D3, which was isolated from a
different bone marrow donor, also had unique HCDR3/LCDR3
sequences and a unique cross-reactivity pattern, and was assigned
to epitope hE2
d (Tables 1,2; Figure 1).
The E1-specific hFabs were isolated using epitope blocking
during the panning process. Blocking with two E2-specific, non-
neutralizing MAbs (F2 and H6) did not have the desired effect of
increasing the isolation of neutralizing Fabs; instead this blocking
seemed to have inhibited binding of E2-specific Fabs since only
E1-specific Fabs were isolated. L1A7 had very limited neutralizing
ability, typical for an E1-specific MAb (Table 1). Fabs K1H3 and
Figure 1. Representative ELISA cross-reactivity patterns for Venezuelan equine encephalitis virus (VEEV) E2-specific human (h)
Fabs and MAbs. A. Anti-hE2
a1 MAb. B. Anti-hE2
a2 Fab. C. Anti-hE2
b Fab. D. Anti-hE2
c MAb. E. Anti-hE2
d Fab. Four varieties of VEEV subtype 1, TC-83
(1AB, –N–), P676 (1C, –&–), 3880 (1D, –m–), and Mena II (1E, –#–); and five other subtypes, EVE (2, –¤–), MUC (3, –%–), PIX (4, –n–), CAB (5, --#--),
and AG80-663 (6, –e–) were included in the panel of ELISA antigens.
doi:10.1371/journal.pntd.0000739.g001
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sequences (two aa differences); these Fabs were assigned to epitope
hE1
a (Tables 1, 2; Figure 2). Anti-hE1
a Fabs were the most cross-
reactive antibodies identified, showing good reactivity with all the
VEEV subtypes tested. Fabs L1A7 and K2E2 had unique
HCDR3 and LCDR3 sequences as well as cross-reactivity
patterns, and were assigned to epitopes hE1
b and hE1
c,
respectively (Tables 1,2; Figure 2).
Competitive binding analysis of hMAbs and hFabs
CBAs were performed by ELISA, using VEEV TC-83 as the
antigen, to determine if there was spatial overlap between epitope
hE2
c, defined by the neutralizing hMAb F5 nIgG, and the epitopes
defined by the other hFabs. Only the homologous F5 Fab or F5 nIgG
was able to compete with F5 nIgG, unconjugated or conjugated to
H R P( T a b l e3 ) .N o n eo ft h ea n t i - h E 2
a2,- h E 2
b,- h E 2
d,- h E 1
a,- h E 1
b,
or -hE1
c Fabs showed .50% competition with F5 nIgG.
CBAs between mMAbs and hMAb F5 were also used to
evaluate the spatial similarity of the hE2
c epitope defined by MAb
F5 nIgG to the previously characterized VEEV E2 epitopes
defined by mMAbs which comprise the major E2 neutralization
domain (E2 aa182–207) [33,34]; competition values .50% were
considered significant (Table 4). The results showed that epitope
hE2
c is most spatially aligned with mMAb-defined epitopes E2
d
and E2
f; antibodies defining these epitopes showed reciprocal or
two-way competition. One-way competitions included F5 nIgG
Figure 2. Representative ELISA cross-reactivity patterns for Venezuelan equine encephalitis virus (VEEV) E1-specific human (h)
Fabs. A. Anti-hE1
a. B. Anti-hE1
b. C. Anti-hE1
c. Four varieties of VEEV subtype 1, TC-83 (1AB, –N–), P676 (1C, –&–), 3880 (1D, –m–), and Mena II (1E,
–#–); and five other subtypes, EVE (2, –¤–), MUC (3, –%–), PIX (4, –n–), CAB (5, --#--), and AG80-663 (6, –e–) were included in the panel of ELISA
antigens.
doi:10.1371/journal.pntd.0000739.g002
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a-HRP and anti-mE2
e-HRP (59% and
56%, respectively); however, neither anti-mE2
a nor anti-mE2
e
could compete with F5-HRP. Murine and humanized anti-E2
c
MAbs 1A4A-1 and Hy4-IgG [43] competed with F5-HRP (92%
and 95%, respectively), but F5 did not significantly block the virus
binding of anti-E2
c 1A4A-1-HRP (20%). Additionally, there was
no competition between F5 and anti-E2
g or anti-E2
h mMAbs.
These analyses indicate that F5 nIgG does not bind to an epitope
within the major neutralization domain on the VEEV E2
glycoprotein defined by mMAbs [33].
Reactivity of F5 nIgG with four anti-VEEV mMAb
neutralization-escape variants
Anti-VEEV mMAb neutralization-escape variants with mutations
in epitopes E2
c,E 2
f,E 2
g,o rE 2
h were evaluated for reactivity with F5
nIgG [36]. If the epitope recognized by F5 were the same as, or near,
any of the changed aa residues (E2-182, 183, 199, and 207) in the
neutralization-escape variant viruses, then F5 would be unable to
neutralize that variant. Results indicated that F5 was able to neutralize
all the variant viruses, including v3B2A-9 which is specific for an E1
epitope (Table 5). F5 nIgG PRNT endpoints were equivalent for all
t h ev a r i a n tv i r u s e sa sw e l la st h ep a r e n tV E E VT C - 8 3 .
Selection of F5 nIgG neutralization-escape variant viruses
MAb F5 nIgG was used to select neutralization-escape variants
of the VEEV TC-83 infectious clone, pVE/IC-92, in order to
more accurately map the binding site of this potent neutralizing
antibody. Two variant (v) viruses were isolated, vF5 nIgG-3 (vF5-
3) and vF5 nIgG-5 (vF5-5), which required either 500- or 2000-
fold more F5 nIgG for neutralization than that needed for
neutralization of parental VEEV TC-83 (Table 6). Neutralization
of these variants was also evaluated with the humanized Hy4 IgG
which is known to bind to the mE2
c epitope (E2 aa182) [36]. The
vF5-5 virus required $4000-fold more Hy4 IgG than the parent
virus for neutralization, and thus was neutralization-resistant for
both F5 nIgG and Hy4 IgG. Although the vF5-3 virus resisted
neutralization with F5 nIgG, Hy4 neutralized this variant as well
as it neutralized VEEV TC-83.
Genomes of the variant and parental VE/IC-92 viruses were
sequenced from nucleotide 8195 to 11421, which includes genetic
information for viral structural proteins E1, E2, E3, 6K and a
portion of the capsid. Mutations in the variant viruses were found
only in the E2 glycoprotein between aa 115–119 (Table 7). The
vF5-3 virus had a transition from A to G at nucleotide 8906,
resulting in a non-conservative amino acid change from Lys to Glu
at E2 aa115. There was also a deletion of nucleotides 8918–8923,
coding for Val (E2 aa119), in the parent virus. The vF5-5 virus had
a silent G to A change at nucleotide 8908, followed by a deletion of
nucleotides 8909–8911, which code for Lys (E2 aa116). The
sequence change at E2 aa115 and deletions at E2 aa116 and 119
in these neutralization-escape variant viruses indicate that F5
binds at this site in the E2 glycoprotein. F5 nIgG neutralizing
activity was somewhat more reduced with vF5-5 virus than with
Table 3. ELISA-based competition of human Fabs with MAb
F5 nIgG for binding to Venezuelan equine encephalitis virus
TC-83.
Competitor
Fab, IgG Epitope
A F5 nIgG-HRP
B
Unconjugated
F5 nIgG
B
F5 nIgG hE2
c 92 Not done
F5 Fab hE2
c 91 63
LR3H11 Fab hE2
a2 26 6
KR2B12 Fab hE2
b 38 4
KR2C2 Fab hE2
b 38 0
951D3 Fab hE2
d 35 0
K2E2 Fab hE1
c 38 18
K1H3 Fab hE1
a 26 0
L1A7 Fab hE1
b 36 0
AEpitopes based on cross-reactivity data (see Table 2.); human (h).
BPercent competition values $50% were considered significant and are shown
in bold font; HRP (horseradish peroxidase).
CHRP, horseradish peroxidase.
doi:10.1371/journal.pntd.0000739.t003
Table 4. Murine and human MAb competition with MAb-hydrogen peroxidase (HRP) conjugates binding to Venezuelan equine
encephalitis virus TC-83.
HRP HRP HRP HRP HRP HRP HRP HRP HRP
Competitor
A Epitope
B a-E2
a a-E2
c a-E2
d a-E2
e a-E2
f a-E2
g a-E2
h a-E1
b a-hE2
c
5B4D-6 E2
a 88
C 1
1A4A-1 E2
c 94 92
1A6C-3 E2
d 92 60
1A3A-5 E2
e 91 0
1A4D-1 E2
f 90 83
1A3A-9 E2
g 94 0
1A3B-7 E2
h 94 0
3B2A-9 E1
b 86 0
F5 nIgG hE2
c 59 20 82 56 68 03 0 892
Hy4 IgG
D E2
c 59 93 96 90 93 52 95 30 95
AUnlabeled competitor MAb is added to ELISA plate 30 min prior to addition of MAb-HRP conjugates.
BMurine epitopes defined in [34]; h (human) epitope.
CHomologous competition controls are underscored; competition percentages $50% were considered significant and are shown in bold font.
DHy4 IgG is a humanized murine MAb with the specificity of the original anti-E2
c MAb [43].
doi:10.1371/journal.pntd.0000739.t004
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binding than the Lys to Glu substitution coupled with the Val
deletion found in the vF5-3 virus.
Discussion
The humoral immune response to VEEV infection in mice has
been well characterized and anti-VEEV mMAbs have played an
essential role in identifying the important antigenic domains of
the virus glycoproteins [33–35]. Although non-human primate
models have been used to evaluate vaccine efficacy of candidate
VEEVs, the antibody repertoires in these primates and humans
have not been well characterized [16,17,53]. Use of phage
antibody libraries generated from immune or nonimmune donors
has proved to be an efficient method for obtaining a diverse set of
non-human primate or human antibodies for a wide variety of
viruses: VEEV [54], human papillomavirus [55], Sin Nombre
virus [56], West Nile virus [57], yellow fever virus (YFV) [58],
rabies virus [59], SARS-coronavirus [60], hepatitis A virus (HAV)
[61], dengue 4 virus (DENV4) [62], rotavirus [63], Hantaan virus
[64], measles virus [65], and HIV [66]. In this study we have
characterized 11 unique hFabs and hMAbs for viral protein
specificity, VEEV subtype cross-reactivity, and virus neutraliza-
tion capacity and constructed the first human epitope map for the
E1 and E2 proteins of an alphavirus. In addition we have
mapped the potential E2 binding site of the potent neutralizing
hMAb F5 nIgG using CBAs with the other hFabs as well as anti-
VEEV mMAbs, and isolated and sequenced the RNA coding for
E1 and E2 glycoproteins of F5 neutralization-escape variant
viruses.
The antibody clones selected for characterization showed good
ELISA binding to VEEV TC-83 and had unique complete gene
sequences; seven hMAbs were specific for the E2 glycoprotein and
four for E1. Only two neutralizing hFabs, F5 and L1A7, were
isolated, despite the use of a blocking strategy during panning to
favor selection of such antibodies. A similar strategy was used,
without much success, in an attempt to favor selection of West Nile
virus hMAbs specific for domain III of the envelope glycoprotein
[57]. The anti-E2 specific F5 nIgG had a 70% PRNT endpoint of
10 ng/ml, equivalent to that described for the most effective
neutralizing anti-VEEV E2 mMAbs (Table 1) [33,34]. Poorer
neutralization titers for human or chimpanzee Fabs or MAbs
specific for YFV, DENV4 or HAV have been reported: 0.1–3 mg/
ml, 0.2–0.6 mg/ml, and 0.5 mg/ml, respectively [58,61,62]. The
E1-specific hFab L1A7 had a PRNT endpoint of 3 mg/ml, 300-
fold lower than F5. The titer might be higher for a complete IgG
antibody, but typically neutralization titers for anti-E1 mMAbs are
less than anti-E2 mMAbs [34].
A high degree of cross-reactivity for the various VEEV
subtypes and varieties was found for the E2-specific hMAbs and
hFabs compared to the spectrum of type-specific to subgroup-
reactive reactivities shown by the well-characterized mMAbs
(Table 1) [33,34,67]. In fact, no VEEV type-specific hMAbs
were isolated. The methodology for generating the mMAbs was
different from that used in this study, but in all studies screening
was done on plate-bound, purified virus and clones were
selected that had the highest level of binding by ELISA. The
virus used for panning in this study was inactivated with either
0.3% or 0.05% BPL, while live virus was used in ELISAs to
select mMAbs. However, the BPL-treated virus was reactive
with neutralizing mMAbs in ELISA and it was assumed that
neutralizing hMAbs would also bind this antigen. HMAb F5
nIgG was originally selected using 0.3% BPL-treated virus, but
it was later discovered that its binding to live virus was 50–75%
greater (Table S2); therefore, the amount of BPL used was
decreased to 0.05%, which improved F5 binding (data not
shown). The fact that the binding of mMAbs was not affected
by treating virus with 0.3% BPL, but binding of hMAb F5 was
Table 5. Neutralization of five murine MAb neutralization-escape variants of Venezuelan equine encephalitis virus (VEEV) TC-83 by
human MAb F5 nIgG.
70% PRNT endpoint
D 70% PRNT endpoint
Virus/variant
A Epitope
B Variant aa
C F5 nIgG ng/ml Homologous mMAb mg/ml
VEEV TC-83 — — 6.25 —
v3B4C-4 E2
c E2 aa 182 12.5 .100
v1A4D-1 E2
f E2 aa 183 12.5 $100
v1A3A-9 E2
g E2 aa 199 6.25 50
v1A3B-7 E2
h E2 aa 207 6.25 100
v3B2A-9 E1
b — 6.25 ,1:100 (MAb ascites)
AVariant (v) virus designation is the name of the MAb used to generate each variant [36].
BEpitope designation for each MAb used to create the neutralization-escape variant virus.
CLocation of the E2 protein amino acid (aa) change for each variant.
DPRNT, plaque-reduction neutralization test; a 70% PRNT endpoint is given in ng/ml for F5 and mg/ml for each homologous murine (m) MAb.
doi:10.1371/journal.pntd.0000739.t005
Table 6. Comparison of the neutralization activity of
humanized murine MAb Hy4 IgG and fully human MAb F5
nIgG for parental Venezuelan equine encephalitis virus (VEEV)
TC-83 and F5 nIgG neutralization-escape variant viruses vF5
nIgG-3 and vF5 nIgG-5.
Virus,
variant (v)
F5-
PRNT-1
a
F5-
PRNT-2
a
Hy4-
PRNT-1
b
Hy4-
PRNT-2
b
vF5 nIgG-3 6.25 (500)
c 6.25 (500) ,0.05 (,2) 0.047 (3.75)
vF5 nIgG-5 25 (2000) 18.8 (1500) .100 (.4000) 50 (4000)
VEEV TC-83 0.0125 0.0125 0.025 0.0125
aPRNT (plaque-reduction neutralization test) using F5 nIgG; 70% PRNT
endpoints are reported in mg/ml of MAb.
bPRNT using Hy4 IgG; 70% PRNT endpoints are reported in mg/ml of MAb.
cFold difference in PRNT endpoints between variant and parental VEEV TC-83
are shown in parentheses.
doi:10.1371/journal.pntd.0000739.t006
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neutralizing mMAbs and hMAb F5 may not be the same.
The ELISA binding affinity of the three human IgG antibodies,
F5, H6, and G1, for VEEV TC-83 was equivalent to that of
mMAb 3B4C-4 (Figure S4). Both F5 nIgG and 3B4C-4 are potent
neutralizing MAbs while neither H6 eIgG nor G1eIgG have
biological activity, so in this case high affinity was not necessarily
correlated with neutralization capacity. CBA analysis indicated
that the hE2
c epitope defined by F5 nIgG does not spatially
overlap any of the other epitopes defined by the panel of hFabs
(Table 3). The cross-reactivity profile of this hMAb was also
unique (Table 1, Figure 1). CBA results comparing F5 and a panel
of mMAbs important in defining a major VEEV E2 neutralization
domain suggested that epitopes mE2
d and mE2
f were spatially
near epitope hE2
c based on reciprocal competition patterns
(Table 4). The mE2
f epitope has been mapped to residue E2-183,
but mE2
d has not yet been mapped [36]. However, in the original
description of this neutralization domain defined by mMAbs, there
was no direct competition between mE2
d and mE2
f [33]. Further
analysis revealed that F5 neutralized all four mMAb neutraliza-
tion-escape variant viruses to the same degree as the parent VEEV
TC-83, indicating that binding of F5 was not affected by an aa
change at either E2-182, -183, -199 or -207, providing important
evidence that F5 recognized a different E2 epitope than any of the
four neutralizing mMAbs used to generate the variant viruses
(Table 5).
We isolated two neutralization-escape variant viruses of F5
nIgG, vF5-3 and vF5-5, and sequenced their structural protein
genes to locate the theoretical binding site of this hMAb. Based
on the aa changes in the variant viruses, F5 binding was mapped
Table 7. Sequence comparisons between Venezuelan equine
encephalitis virus TC-83 (VE/IC-92) and two F5 nIgG
neutralization-escape variant viruses vF5 nIgG-3 and vF5
nIgG-5.
Nucleotide sequence (nt 8906–8923)
Virus, variant (v) nt/aa E2 amino acid sequence (aa 115–120)
TC-83 (VE/IC-92) nt AAG AAA GAT TCC GTC AGA
aa K K D S V R
vF5 nIgG-3 nt GAG AAA GAT TCC ---
a AGA
aa E KDS R
vF5 nIgG-5 nt AAA --- GAT TCC GTC AGA
aa K D S V R
a---, deleted sequence.
doi:10.1371/journal.pntd.0000739.t007
Figure 3. Mapping the E2 ectodomain. A. A top view of the E2 density of one spike looking down the 3-fold axis (shown as the large purple spot
corresponding to three merged carbohydrate moieties at position 46). B. A side view of one E2 molecule with the approximate location of
Venezuelan equine encephalitis virus (VEEV) E2 peptide 13 (amino acids 241–265) shown in black. A and B: The markers on the E2 glycoprotein that
correspond to carbohydrate moieties at positions 46, 160, 196, 200, 216, 262, and 318 are shown in purple, red, blue, orange, green, pink, and light
blue, respectively. Position 216 (green) was also identified with a cryoEM map of a Fab-Ross River virus complex. Approximate locations of the VEEV
murine MAb anti-mE2
c binding site and critical neutralization site are shown by a dotted circle; the proposed binding site of the VEEV human MAb
anti-hE2
c is shown in cyan.
doi:10.1371/journal.pntd.0000739.g003
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substitution in vF5-5 and vF5-3 viruses alter the net charge or
degree of hydrophilicity in this E2 region, possibly affecting the
accessibility of this epitope for antibody binding. Variant virus
vF5-5 was more resistant than vF5-3 to neutralization with F5,
although both variant viruses required significantly more MAb
for neutralization than required for VEEV TC-83 (Table 6). We
also tested whether or not the humanized mMAb Hy4 IgG,
specific for the mE2
c epitope, could neutralize these two variant
viruses. If the binding sites for F5 and Hy4 are different, it would
be expected that Hy4 would neutralize both F5 variant viruses.
However, only vF5-3 was neutralized, and vF5-5 was as resistant
to neutralization by Hy4 as it was to F5. This rather puzzling
result, in addition to the reciprocal competition between F5 and
the anti-E2
f mMAb, might suggest some type of interaction or
induced conformational change between the neutralization
domains located at E2 aa182–207 and E2 aa115–119. Of course
the possibility cannot be excluded that the detected mutations are
not the contact residues for F5, but that these amino acid
substitutions or deletions induce distant conformational changes
that affect MAb binding.
The identification of a novel neutralization domain on the
VEEV E2 glycoprotein is analogous to the identification of a
second neutralization domain on SV, identified using anti-E2c
MAbs R6 and R13 neutralization-escape variant viruses that
contained a coding change at either E2 aa62, 96, or 159 [68].
It was proposed that these E2 residues that formed an
alternative neutralization site could be folded to form a binding
site with the surface dimensions of approximately 600–750 A ˚,
measurements similar to those determined for the interaction of
lysozyme–anti-lysozyme immune complexes [69]. Transposon-
insertion mutagenesis of SV resulted in a virus with an insertion
at E2-119 that was less efficiently neutralized by SV mMAbs
202 (anti-E2ab) and 209 (anti-E2c) [70]. Similarly, a variant of
RRV, attenuated in mice, had five E2 aa differences compared
to wild-type at positions 3, 67, 119, 251, and 302 [39]. Residue
251 lies in the major neutralization domain, whereas residues
67 and 119 were proposed to influence neutralization efficiency
in the variant virus. Examination of VEEV E2 mutations that
affect virus binding to heparan sulfate led to a proposal that E2
residues 76 and 116 may form a conformational, surface-
accessible epitope, but its involvement with virus neutralization
is unknown [71].
Although the crystal structure of the alphavirus E2 glycopro-
tein has not been solved, cryoEM reconstructions of E2 have
been reported [25,30,72]. The 9A ˚ resolution cryoEM map of
the SV E2 presented by Mukhopadhyay et al. [72] was
annotated with markers representing locations of glycosylation
sites, the protein N-terminus, and a neutralizing Fab binding
site. We have adapted their figure to show the probable surface-
accessible location of the hMAb F5 nIgG binding site (E2
aa115–119) and its relationship with other markers (Figure 3A,B).
Mapping of this epitope to a unique E2 neutralization site was
based on the data presented in this study: (1) epitope binding by
hMAb F5 nIgG was more sensitive to 0.3% BPL treatment than
epitopes recognized by neutralizing mMAbs, (2) hMAb F5 was
able to neutralize all anti-VEEV mMAb neutralization escape
variant viruses and therefore did not bind to E2 residues 182–
207, defined as the ‘‘critical’’ neutralization domain, and (3)
hMAb F5 neutralization escape variant viruses vF5-3 and vF5-5
defined a neutralization epitope involving E2 aa115–119.
Results from studies in mice using VEEV E2 synthetic peptides
as vaccines have been included in the proposed map of the E2
ectodomain to complement the placement of the hE2
c epitope
(Figure 3B). Previously, we identified two peptide vaccines,
VE2pep01 (E2 aa1–25) and VE2pep13 (E2 aa241–265) that
protected mice from virulent VEEV challenge [73–75]. We also
isolated an anti-peptide MAb, 1A2B-10, specific for E2 aa1–19,
which passively protected mice challenged with VEEV varieties
1AB, 1C, and 1D [76]. None of the anti-peptide antibodies,
either polyclonal or monoclonal, had virus-neutralizing activity,
indicating that their cognate peptides were not likely to be
surface-accessible or lacked the appropriate conformation. The
proposed configuration of the E2 molecule shown in Fig. 3B
places the hE2
c epitope (E2 aa115–119) on the surface of the
spike above the more cryptic locations of the E2 N-terminus
(VE2pep01) and aa 241–265 (VE2pep13). Such an arrangement
would be in agreement with the current knowledge of the
structure of the E2 glycoprotein, the location of specific markers,
and functional attributes of specified epitopes. We are now in
collaboration to obtain structural data on Fab-virion complexes
to determine actual binding sites of F5 nIgG and other human
and murine MAbs.
The VEEV neutralizing ability of the hMAb F5 nIgG is similar
to that exhibited by the humanized mMAb Hy4 IgG. When
administered prophylactically, as little as 100 ng of Hy4 was able
to protect 90% of mice challenged intraperitoneally with virulent
VEEV [43]. In addition, Hy4 given one or 24 h after VEEV
infection cured 90% or 75% of infected mice, respectively. F5
nIgG would be expected to be as effective an immunotherapeutic
as Hy4 IgG. Administration of a cocktail of the two MAbs, which
bind to different epitopes, could provide increased protection
against generating virulent VEEV neutralization-escape variants
in vivo.
Supporting Information
Figure S1 Cloning of Fabs into the expression vector PAEV1.(A)
Light and heavy chains of selected Fabs were inserted into vector
PAEV1 at Eco RI/Spe I sites. (B) Fabs with light chains containing
Eco RI sites were inserted into vector PAEV1 (containing the light
and heavy chains of Fab L1A7) at Xba I/Age I sites.
Found at: doi:10.1371/journal.pntd.0000739.s001 (0.06 MB PPT)
Figure S2 Schematic presentation of conversion of Fabs to
engineered IgG (eIgG). A fragment containing mammalian control
elements was inserted into each Fab at Not I and Xho I sites in the
PAX243 Fab vector. The Sfi I to Age I fragment containing the
light chain, mammalian control elements, and the heavy chain was
transferred to an IgG expression vector containing mammalian
elements upstream of the light chain as well as IgG CH1, hinge,
CH2, and CH3 regions downstream from the heavy chain. Final
construct of eIgG retained the engineered Xba I, Sac I, and Xho I
sites.
Found at: doi:10.1371/journal.pntd.0000739.s002 (0.02 MB PPT)
Figure S3 Conversion of engineered (e) F5 eIG to native (n) F5
nIgG. This conversion was done in a 3 step process: (1) Hind III in
the mammalian control elements for the heavy chain was changed
to Asc I by site-specific mutagenesis and overlap PCR. (2) Xba I
and Sac I sites from the light chain and the Xho I site from the
heavy chain were converted to native sequences by site-specific
mutagenesis and overlap PCR. (3) The engineered Xho I site was
changed to native sequence by site-specific mutation and overlap
PCR.
Found at: doi:10.1371/journal.pntd.0000739.s003 (0.07 MB PPT)
Figure S4 MAbs binding to native Venezuelan equine enceph-
alitis virus TC-83. Human MAbs: F5 nIgG ¤, H6 eIgG N, and
G1eIgG m; murine MAb 3B4C-4 &.
VEEV Human Epitope Map
www.plosntds.org 11 July 2010 | Volume 4 | Issue 7 | e739Found at: doi:10.1371/journal.pntd.0000739.s004 (0.07 MB PPT)
Figure S5 Binding of purified Fabs to inactivated Venezuelan
equine encephalitis virus TC-83. Solid lines are Fab binding to
VEEV TC-83: KR2B12, black inverted triangles; KR2A3, pink
diamonds; LR3H11, blue triangles; K1B11, magenta circles;
KR2C2, black squares; K2E2, green circles; K1H3, orange
diamonds; L1A7, cyan squares; and F5, red squares. The black
circle/dashed line is a representative Fab (K1B11) binding to the
ovalbumin negative antigen control.
Found at: doi:10.1371/journal.pntd.0000739.s005 (0.07 MB PPT)
Table S1 Primers used in reverse transcription PCR and
sequencing reactions.
Found at: doi:10.1371/journal.pntd.0000739.s006 (0.03 MB
DOC)
Table S2 ELISA binding of purified human and murine
Venezuelan equine encephalitis virus (VEEV) MAbs to either
native or 0.3% b-propiolactone (BPL)-treated VEEV TC-83.
Found at: doi:10.1371/journal.pntd.0000739.s007 (0.03 MB
DOC)
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